Drug Trial Radar · NCT07944885
First-in-human Study of SAR448632 in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Aug 15, 2027
Study completion Aug 15, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, first-in-human, placebo-controlled, double-blind, Phase 1 study to assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and target engagement after sequential single ascending doses of SAR448632 in healthy adult male and female participants.
Conditions
- Healthy Volunteer
Interventions
PlaceboDrug
Administration method will match SAR448632
SAR448632Drug
Route of administration: SC injection or infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)Time frame: Baseline to day 113
- Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.Time frame: Baseline to day 113
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.